Symbol not found

:OYST   00:00AM GMT
0.00 (0.00%)
Products, Regulatory

Oyster Point Pharma Submits Phase 2 Clinical Trial Protocol To Evaluate OC-01 Nasal Spray For Neurotrophic Keratitis

Published: 12/01/2020 21:10 GMT
(OYST) - Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate Oc-01 Nasal Spray for Neurotrophic Keratitis (nk).
Oyster Point Pharma Inc - Enrollment of First Patient in Olympia Phase 2 Study in Nk is Planned for First Half of 2021.
Oyster Point Pharma Inc - Remains on Track to File Its NDA for Oc-01 to Treat Signs and Symptoms of Dry Eye Disease in Q4 of 2020.